MONTREAL, Nov. 14, 2017 /CNW Telbec/ - LGC Capital Ltd. (TSXV: LG) ("LGC") is pleased to announce its strategic partner Creso Pharma (CPH-ASX) disseminated the following news release yesterday about the launch of its cannabis-based product anibidiol® in Switzerland and Lichtenstein. Of note, Creso Pharma and LGC have agreed that LGC will be spearheading the distribution of this product in Southern Africa and Canada through LGC's investee businesses, subject to their obtaining all necessary regulatory approvals.
Creso Pharma and Virbac launch anibidiol® - the first Swiss approved hemp product with CBD as a complementary feed for companion animals
Creso Pharma and Virbac are pleased to announce the launch in Switzerland of anibidiol®, a natural complementary feed for companion animals containing a standardized amount of hemp extract with cannabidiol (CBD), the non-psychoactive substance of the hemp plant. The product supports companion animals' immune system, its natural defenses and contributes to balanced behavior. It is now available for the first time to Swiss veterinarians.
anibidiol® is the first Swiss Agroscope conformed complementary feed for companion animals that contains natural hemp extract with CBD and is THC-free.
anibidiol® promotes the well-being of the animal by supporting its immunity and natural defense system. anibidiol® also supports a balanced behavior of the pet.
anibidiol® contains natural full plant hemp extract as well as hemp seed oil. This proprietary combination of CBD, the fatty acids Omega 3, Omega 6 and Omega 9, terpenes, flavonoids, and other active herbal ingredients have a complex interaction which enhances their overall health-promoting effect. The anibidiol® product range directly addresses the need for natural, non-pharmaceutical therapeutic approaches which are well tolerated by animals. The CBD contained in anibidiol® does not cause GI and dependency side effects and has a very good safety and tolerability profile.
In order to guarantee professional advice anibidiol® is marketed in Switzerland exclusively by Virbac and only through veterinary practices. The individually-packed portions contain a granulate formulation, which is mixed once a day with the pet's food.
anibidiol® was developed by Creso Pharma, an Australian-Swiss company based in Zug and Perth. It is produced in Switzerland by Creso's partner Swiss-based food and pharma development company, Domaco, Dr. med Aufdermaur AG (Domaco) and is marketed exclusively in Switzerland by Virbac (Switzerland) AG, Glattbrugg ZH.
Virbac is a global pharmaceutical animal health company with a presence in over 100 countries and more than 4,800 employees and sales subsidiaries in 31 countries. With a turnover of €872 million in 2016, Virbac ranks today as the 7th largest pharmaceutical veterinary company worldwide. Virbac operates through presence in North America (17%), Europe (39%), Latin America (16%), Far East (15%), and Rest of the World (13%). Its wide range of vaccines and medicines are used in the prevention and treatment of the main pathologies for companion and food-producing animals.
Creso Pharma CEO and Co-Founder Dr. Miri Halperin Wernli said: "We are very excited to launch anibidiol® in Switzerland and thrilled to be working in partnership with Virbac, such a well-established global company in the animal health field. This is the first introduction of our hemp-based complementary feed products for companion animals in the veterinary market. "It is a particularly significant launch for us as it is Creso's first product launch in Europe and we intend to follow it with many more. "We look forward to working with Virbac to successfully promote, market and launch further quality hemp-based animal health products." The recession-resistant worldwide animal health market is estimated to be USD 30 billion1 and is projected to continue to show rapid growth. Forty-one per cent of pet owners have considered or tried various alternative therapies including nutritional supplements (29%) and herbal remedies (7%).2
Creso Pharma Switzerland is a subsidiary of Creso Pharma Limited, based in Perth, Australia, and listed on the Australian stock exchange ASX. Creso Pharma Switzerland develops, produces and markets worldwide hemp-based innovative nutraceutical products for humans and complementary feed products for animals. In Switzerland, Creso Pharma Switzerland markets its products for animal health with Virbac (Switzerland) AG. www.anibidiol.com
Virbac (Switzerland) Ltd., headquartered in Zurich-Glattbrugg, is part of the Virbac Group from France, which is dedicated exclusively to animal health, in more than 100 countries and on all five continents. Virbac (Schweiz) AG has a wide range of innovative health products for the prophylaxis and treatment of the most important diseases of domestic animals and livestock.
1 Vetnosis review 2016
2 Brown, L. P. (2001) Pet nutraceuticals: hype or wave of the future? Nutraceuticals World. January/February 2001 issue, pp. 34–41. Retrieved 31st July 2017 from: http://www.nutraceuticalsworld.com/issues/2001‐01/view_features/petnutraceuticals/
About Creso Pharma
Creso Pharma brings pharmaceutical expertise and methodological rigour to the world of medicinal cannabis and strives for the highest quality in its products. It is the leader in medicinal cannabis and cannabidiol (CBD) innovation and develops cannabis- and hemp-derived therapeutic-grade nutraceuticals and medicinal cannabis products with wide patient and consumer reach for human and animal health. Creso uses GMP development and manufacturing standards for its products as a reference of quality excellence with initial product registrations in Switzerland. It has worldwide rights for a number of unique and proprietary innovative delivery technologies which enhance the bioavailability and absorption of cannabinoids.
About Domaco, Dr. med Aufdermaur AG
Domaco, Dr. med Aufdermaur AG is a Swiss-based food and pharma development company that owns the rights to a number of innovative delivery systems used to administer active ingredients through galenic forms which is a way of preparing and compounding medicines in order to optimise their absorption.
About LGC Capital Ltd.:
LGC Capital Ltd. is a Canadian incorporated public company listed on the TSX Venture Exchange (TSXV: LG). LGC's is a diversified investment company with core holdings in businesses that provide shareholders with exposure to a diverse range of high growth businesses, products and services. To date, LGC has entered into agreements for investments in private cannabis operations in South Africa, Australia and Canada. The company also has a strategic alliances with AfriAg (Pty) Ltd. to grow and distribute medical and recreational cannabis products in the southern African region for export to regulated and certified end users around the world; and with Creso Pharma Limited for the creation of a vertically-integrated cannabis operation, which includes cultivation, IP generation, product development, and commercialization. LGC Capital Ltd. is headquartered in Montreal, Canada.
This press release may contain forward-looking statements with respect to LGC Capital Ltd. ("LGC") and Creso Pharma Limited ("Creso") and their respective operations, strategy, investments, financial performance and condition. These statements generally can be identified by use of forward-looking words such as "may", "will", "expect", "estimate", "anticipate", "intends", "believe" or "continue" or the negative thereof or similar variations. The actual results and performance of LGC and Creso, including their proposed strategic alliance described herein, could differ materially from those expressed or implied by such statements. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding future expectations. Some important factors that could cause actual results to differ materially from expectations include, among other things, general economic and market factors, competition, government regulation and the factors described under "Risk Factors and Risk Management" in LGC's Management's Discussion and Analysis for the fiscal year ended September 30, 2016, as filed on SEDAR (www.sedar.com). The cautionary statements qualify all forward-looking statements attributable to LGC or Creso, as the case may be, and persons acting on their behalf, respectively. Unless otherwise stated, all forward-looking statements speak only as of the date of this press release and neither LGC nor Creso has any obligation to update such statements, except to the extent required by applicable securities laws.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE LGC Capital Ltd
For further information: Company & Media Contacts, Canada contact: John McMullen, Chief Executive Officer, Tel.: (416) 803-0698, Email: John@lgc-capital.com; London contact: Anthony Samaha, Chief Financial Officer, Tel.: +44 (0) 20 7440 0640; Investor Relations contact: Dave Burwell, The Howard Group Inc., Tel.: (403) 221-9015, Toll Free: 1-888-221-0915, Email: firstname.lastname@example.org